differentiated thyroid cancer

Reevaluating Radioactive Iodine Therapy in T3b Differentiated Thyroid Cancer: Insights from a SEER-Based Cohort Study

By MedXY 09/17/2026

This cohort study of 6,638 T3b differentiated thyroid cancer patients found no survival benefit from adjuvant radioactive iodine therapy, suggesting the need for individualized treatment strategies and prospective studies focusing on recurrence outcomes.

Diabetes & Endocrinology news Oncology

Accelerating Radioiodine Therapy in Differentiated Thyroid Cancer: A Novel 24-Hour Diagnostic 131I Scan Protocol Post-rhTSH Administration

By MedXY 08/25/2026

A novel protocol performing diagnostic 131I scans within 24 hours after the second rhTSH injection reliably guides radioiodine therapy in differentiated thyroid cancer, enabling same-cycle pre-treatment evaluation and treatment without schedule alteration.

Diabetes & Endocrinology news Oncology

Long-Term Fatigue in Differentiated Thyroid Cancer Survivors: Early Predictors and the Non-Impact of Thyrotropin Suppression

By MedXY 08/21/2026

A nationwide prospective study identifies early fatigue and poor mental health as key predictors of long-term fatigue in differentiated thyroid cancer patients, while thyrotropin suppression shows no association with fatigue.

news Oncology Pediatrics

Long-Term Risk of Second Primary Malignancies in Pediatric and Young Adult Differentiated Thyroid Cancer Survivors: A Four-Decade Real-World Study

By MedXY 08/17/2026

Pediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailored therapy.

Diabetes & Endocrinology Family Medicine & Nutrition news

Can Long-Term Thyroid Cancer Follow-Up Safely Move to Primary Care? Prospective Data Support De-Escalation After Excellent Response

By MedXY 05/26/2026

A prospective cohort study suggests that differentiated thyroid cancer patients with sustained excellent response after at least 5 years of specialist follow-up can be safely transitioned to primary care with very low recurrence risk.

news Oncology Pathology & Lab Medicine/Bệnh học

TSH Stimulation Methods Show Comparable Outcomes in Radioiodine-Avid Metastatic Differentiated Thyroid Cancer

By MedXY 05/16/2026

In radioiodine-avid metastatic differentiated thyroid cancer, rhTSH and mixed rhTSH/thyroid hormone withdrawal preparation produced comparable adjusted outcomes. Prognosis was driven mainly by metastatic burden and age, supporting individualized treatment selection.

Cardiology Diabetes & Endocrinology news OB/GYN & Women's Health

Prolonged TSH Suppression in Postmenopausal Thyroid Cancer Patients Linked to Worse Cardiovascular and Quality-of-Life Outcomes

By MedXY 04/28/2026

Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

By MedXY 08/02/2025

The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.